Skip to main content
CRMD
NASDAQ Life Sciences

CorMedix 10-Q: Material Weakness Persists as DefenCath Revenue Falls to $17.2M

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$5.15
Mkt Cap
$413.105M
52W Low
$5.1
52W High
$13.02
52W Position info
1.0% above low
Off High info
60% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

CRMD is trading near its 52-week low of $5.1 (1.0% above the low).

Summary

CorMedix's Q3 10-Q confirms the $54.5 million revenue beat but shows DefenCath sales down to $17.2 million on the CMS reimbursement reset, an unremediated material weakness in controls, and a new post-quarter impairment indicator.


Key Events · Earnings and Guidance · CRMD

  • Material Weakness Still Unremediated

    Management concluded disclosure controls were not effective at September 30, 2026 due to the previously disclosed material weakness over review of significant non-routine transactions; it remains unremediated.

  • DefenCath Revenue Collapses Post-TDAPA

    DefenCath net revenue was $17.2 million in Q3 versus $88.8 million a year earlier after CMS cut the post-TDAPA add-on to $2.37 per dialysis treatment; total revenue of $54.5 million still beat the $51.2 million consensus.

  • Net Loss Is Mostly Non-Cash

    The $14.7 million net loss, or $(0.19) per share, included an $11.5 million non-cash change in fair value of Melinta contingent consideration — a remeasurement, not a cash outflow or new dilution.

  • Impairment Indicator Flagged

    The filing states the post-September 30 decline in share price and market capitalization could be an impairment indicator requiring an interim goodwill and long-lived asset assessment.


Analysis · CRMD · Life Sciences

The headline numbers were already out this morning, but the 10-Q adds two things that change how the quarter should be read. First, disclosure controls were still not effective at September 30, 2026 because of the previously disclosed material weakness in reviewing significant non-routine transactions — it has not been remediated, which matters with a $145 million Heron acquisition and a new $150 million term loan now on the books. Second, the DefenCath collapse is now in the statements: Q3 product sales of $17.2 million versus $88.8 million a year ago after CMS reset the post-TDAPA add-on to $2.37 per treatment, and the $14.7 million net loss is mostly an $11.5 million non-cash remeasurement of Melinta contingent consideration rather than cash burn. Cash of $355.2 million and $218.3 million of nine-month operating cash flow keep the balance sheet comfortable, but the filing also flags that the post-quarter stock decline could force an interim impairment test on goodwill and intangibles.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 48.1% of the 1752 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CRMD was trading at $5.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $413.1M. The 52-week trading range was $5.10 to $13.02. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CRMD - Latest Insights

CRMD
Nov 12, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.25
Real-time Price: $5.16 info
Change: -$0.090 (-2%) info
Market Cap: $413.105M info
CRMD
Nov 12, 2026, 7:30 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $5.25
Real-time Price: $5.16 info
Change: -$0.090 (-2%) info
Market Cap: $413.105M info
CRMD
Nov 09, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $5.50
Real-time Price: $5.16 info
Change: -$0.340 (-6%) info
Market Cap: $413.105M info
CRMD
Nov 02, 2026, 7:39 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.50
Real-time Price: $5.16 info
Change: -$0.340 (-6%) info
Market Cap: $413.105M info
CRMD
Nov 02, 2026, 7:32 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $5.62
Real-time Price: $5.16 info
Change: -$0.4555 (-8%) info
Market Cap: $413.105M info